Award of CE Mark Certificate

RNS Number : 6990Q

Futura Medical PLC

17 October 2013

 



For immediate release

17 October 2013

 

 

Futura Medical plc

("Futura" or the "Company")

Award of CE Mark Certificate

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce the award of the CE mark certificate for CSD500, the Company's novel condom.

CSD500 is clinically proven to produce a firmer erection and increase penile size in healthy men whilst wearing a condom during sexual intercourse and to give women a longer lasting sexual experience.

The award of the CE mark means that CSD500 can be marketed in all European territories and also in a number of non-European territories that recognise the CE mark process.

Steven Cugine, Church & Dwight's President of International Consumer Products, commented: "We congratulate Futura on gaining regulatory approval in Europe for CSD500 and we look forward to continuing to work with Futura towards the launch of this extremely novel condom."

James Barder, Futura's Chief Executive, commented: "We are delighted to receive the CE mark certificate for CSD500. This means that the product is now approved for marketing throughout Europe, where it has already been licensed to Church & Dwight, owner of the highly trusted Trojan brand, in certain key territories. Discussions are proceeding well with potential licensing partners for other territories within Europe, and also for other territories worldwide." 

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
Cenkos Securities plc
Bobbie Hilliam	Tel:[phone]
For media enquiries please contact:
Buchanan
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

MSCBLBDGRDBBGXL